Novo Integrated Sciences Acquires Majority Stake in Terragenx and Intellectual Property for FDA and Health Canada Approved Water-Soluble Iodine Micro-Nutrient
2021年11月30日 - 10:00PM
ビジネスワイヤ(英語)
Iodine, an essential nutrient, when in
aerosolized aqueous form can be safely ingested to kill bacteria
and deactivate various viruses
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or
“Novo”), pioneering a holistic approach to patient-first health and
wellness through a multidisciplinary healthcare ecosystem of
services and product innovation, announced today it has acquired
91% of Terragenx and the intellectual property portfolio for the
unique formulation and manufacturing capability to produce a
water-soluble iodine micro-nutrient that is FDA and Health Canada
approved for over-the-counter and e-commerce distribution (the
“Iodine IP and Patents”).
Iodine is a naturally occurring element and essential nutrient
used by the thyroid gland to manufacture necessary hormones in the
human body. While iodine alone cannot be ingested, Novo has
acquired the intellectual property for iodine in an aqueous form
that can be safely ingested and has been proven to kill viruses,
bacteria and protozoa when sprayed onto your mucous membranes, the
entry points for various airborne viruses. The human immune system
uses iodine to deactivate viruses in the bloodstream, which may
facilitate the production of antibodies for various
indications.
Robert Mattacchione, Novo’s Chairman and CEO, stated, “We are
pleased to acquire yet another valuable intellectual property
portfolio and brand to immediately incorporate into our
multidisciplinary healthcare ecosystem. Iodine has important health
attributes that when administered in a water-soluble form via the
nasal or oral passageways has instant benefits to combat disease,
bacteria, and viruses. Already being sold in the U.S. and Canada,
we strongly believe that together we will be able to accelerate the
growth of the existing Iodine IP and Patent product portfolio as
well as launch new products to market.”
Novo acquired a 91% interest in Terragenx through an all-share
transaction at $3.35 per share which closed November 17, 2021. On
the same date, Novo acquired the Iodine IP and Patents from Terence
Mullins, the inventor, in an all-share transaction at $3.35 per
share.
About Novo Integrated Sciences,
Inc.
Novo Integrated Sciences, Inc. is pioneering a holistic approach
to patient-first health and wellness through a multidisciplinary
healthcare ecosystem of services and product innovation. Novo
offers an essential and differentiated solution to deliver, or
intend to deliver, these services and products through the
integration of medical technology, advanced therapeutics, and
rehabilitative science.
We believe that “decentralizing” healthcare, through the
integration of medical technology and interconnectivity, is an
essential solution to the rapidly evolving fundamental
transformation of how non-catastrophic healthcare is delivered both
now and in the future. Specific to non-critical care, ongoing
advancements in both medical technology and inter-connectivity are
allowing for a shift of the patient/practitioner relationship to
the patient’s home and away from on-site visits to primary medical
centers with mass-services. This acceleration of “ease-of-access”
in the patient/practitioner interaction for non-critical care
diagnosis and subsequent treatment minimizes the degradation of
non-critical health conditions to critical conditions as well as
allowing for more cost-effective healthcare distribution.
The Company’s decentralized healthcare business model is
centered on three primary pillars to best support the
transformation of non-catastrophic healthcare delivery to patients
and consumers:
- First Pillar: Service Networks. Deliver multidisciplinary
primary care services through (i) an affiliate network of clinic
facilities, (ii) small and micro footprint sized clinic facilities
primarily located within the footprint of box-store commercial
enterprises, (iii) clinic facilities operated through a franchise
relationship with the Company, and (iv) corporate operated clinic
facilities.
- Second Pillar: Technology. Develop, deploy, and integrate
sophisticated interconnected technology, interfacing the patient to
the healthcare practitioner thus expanding the reach and
availability of the Company’s services, beyond the traditional
clinic location, to geographic areas not readily providing
advanced, peripheral based healthcare services, including the
patient’s home.
- Third Pillar: Products. Develop and distribute effective,
personalized health and wellness product solutions allowing for the
customization of patient preventative care remedies and ultimately
a healthier population. The Company’s science-first approach to
product innovation further emphasizes our mandate to create and
provide over-the-counter preventative and maintenance care
solutions.
Innovation through science combined with the integration of
sophisticated, secure technology assures Novo Integrated Sciences
of continued cutting edge advancement in patient first
platforms.
For more information concerning Novo Integrated Sciences, please
visit www.novointegrated.com. For more information on NHL,
please visit www.novohealthnet.com
Twitter: https://twitter.com/novointegrated LinkedIn:
https://www.linkedin.com/company/60376520/admin/ Facebook:
https://www.facebook.com/novointegrated/ Instagram:
https://www.instagram.com/novointegrated/ YouTube:
https://www.youtube.com/channel/UCy3wpEIfQwwaf0BZ-34OKwQ
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts
included in this press release are forward-looking statements. In
some cases, forward-looking statements can be identified by words
such as "believe," “intend,” "expect," "anticipate," "plan,"
"potential," "continue" or similar expressions. Such
forward-looking statements include risks and uncertainties, and
there are important factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements. These factors, risks and uncertainties
are discussed in Novo’s filings with the Securities and Exchange
Commission. Investors should not place any undue reliance on
forward-looking statements since they involve known and unknown,
uncertainties and other factors which are, in some cases, beyond
Novo’s control which could, and likely will, materially affect
actual results, levels of activity, performance or achievements.
Any forward-looking statement reflects Novo’s current views with
respect to future events and is subject to these and other risks,
uncertainties and assumptions relating to operations, results of
operations, growth strategy and liquidity. Novo assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. The contents of any website referenced in
this press release are not incorporated by reference herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211130005276/en/
Chris David, COO-President Novo Integrated Sciences, Inc.
chris.david@novointegrated.com (888) 512-1195
Novo Integrated Sciences (NASDAQ:NVOS)
過去 株価チャート
から 6 2024 まで 7 2024
Novo Integrated Sciences (NASDAQ:NVOS)
過去 株価チャート
から 7 2023 まで 7 2024